Q2 FY26 Quarterly Activities Report and Appendix 4C
| Stock | Alcidion Group Ltd (ALC.ASX) |
|---|---|
| Release Time | 15 Jan 2026, 8:46 a.m. |
| Price Sensitive | Yes |
Alcidion Group Ltd reports Q2 FY26 results
- Selected as preferred supplier for University Hospitals Sussex NHS Foundation Trust EPR solution
- Q2 new TCV sales of $15.4M, including $12.3M expansion for Miya Precision with Leidos
- FY26 contracted revenue up 40% on prior year, with further upside anticipated
Alcidion Group Limited (ASX:ALC) has released its Appendix 4C and Quarterly Activities Report for the quarter ended 31 December 2025 (Q2 FY26). Highlights include being selected as the preferred supplier by University Hospitals Sussex NHS Foundation Trust (UHSussex) for its new Electronic Patient Record (EPR) solution, with the total contract value (TCV) expected to be at least $35M. In Q2, the company achieved new TCV sales of $15.4M, including a $12.3M expansion for additional software modules from Miya Precision to enable Leidos to deliver further solution components to the Commonwealth of Australia. The company also reported several existing contract renewals. As of 31 December 2025, Alcidion has FY26 contracted (sold and renewal) revenue of $43.1M, up 40% on the prior corresponding period and 6% up on FY25 full year revenue. The company expects a material uplift in H2 FY26 customer receipts compared to H1, and FY26 EBITDA and cash flow are expected to be at least in line with FY25, with potential upside dependent on the successful completion of the University Hospitals Sussex contract and continued conversion of new revenue opportunities.
Building on its strong first half performance, Alcidion expects full year FY26 EBITDA and cash flow to be at least in line with FY25, with potential upside dependent on the successful completion of the University Hospitals Sussex contract and continued conversion of new revenue opportunities.
Alcidion has FY26 contracted (sold and renewal) revenue of $43.1M, up 40% on the prior corresponding period and 6% up on FY25 full year revenue. This does not include any revenue contribution from the University Hospitals Sussex EPR contract negotiation nor other potential new contract wins which may occur over the course of the second half of the financial year. The company expects a material uplift in H2 FY26 customer receipts compared to H1.